COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Ability of Home Monitoring® to Detect and Manage the Inappropriate Diagnoses in Implantable Cardioverter Defibrillators. (THORN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01594112
Recruitment Status : Completed
First Posted : May 8, 2012
Last Update Posted : March 17, 2017
Information provided by (Responsible Party):
Biotronik SE & Co. KG

Brief Summary:

The purpose of the THORN registry is to show the ability of Home-Monitoring® to early identify and manage the inappropriate diagnoses of ventricular arrhythmia in ICD patients (i.e. lead rupture, atrial arrhythmia, oversensing…) whatever the type of device (single, dual, or triple chamber).

The electromyograms (iEGMs) provided by Remote Patient Monitoring will help the physician to early detect inadequate arrhythmia detection (ID) that can be responsible for inappropriate therapies (IT), and to take preventive actions in order to reduce the burden of these inappropriate therapies.

THORN is an observational epidemiologic, prospective and multicenter registry. The primary objective is to measure the relative proportion of patients experiencing at least one inappropriate therapy during a fifteen months follow-up period. Moreover, THORN will assess the incidence, predictors, outcome and recurrence of inappropriate diagnoses in 1750 ICD patients.

Condition or disease
ICD Sudden Cardiac Death Ventricular Fibrillation Atrial Fibrillation Ventricular Tachycardia

Detailed Description:

Remote Patient Monitoring allows early detection of events that can generate inadequate detection of ventricular arrhythmia (i.e. lead rupture, atrial arrhythmia, oversensing….) and be responsible for inappropriate therapies. In such cases, it may be assumed that physicians can react earlier and take preventive actions, in order to reduce the risk or burden of inappropriate therapies.

The THORN registry has two purposes:

  • To determine retrospectively the relative proportion of patients experiencing at least one inappropriate therapy during 15-months of follow-up, in ICD patients equipped with Home Monitoring®. This part concern 1240 patients.
  • To evaluate prospectively the relationship between the detection of inappropriate diagnosis (with or without subsequent inappropriate therapy), the corrective action taken, and the recurrences of inappropriate diagnosis of the same origin/mechanism. This part concerns 510 patients.

BIOTRONIK Home Monitoring® by iEGM-Online® with Biotronik ICD devices (LUMAX) systematically stores any episode classified as ventricular tachycardia (VT) or ventricular fibrillation (VF) which is transmitted to the physician.

In the THORN study, in addition to the physicians' analysis, all electromyograms will be reviewed by an adjudication committee in order to classify them as appropriate or inappropriate diagnosis.

Layout table for study information
Study Type : Observational
Actual Enrollment : 512 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Inappropriate Therapies and Home Monitoring® in Implantable Cardioverter Defibrillators (ICD)
Actual Study Start Date : March 15, 2012
Actual Primary Completion Date : September 27, 2013
Actual Study Completion Date : April 1, 2015

Patient with at least one ID
Patient with ICD who received at least one inappropriate diagnosis (with or without therapy) during the 15 months follow-up.

Primary Outcome Measures :
  1. Relative proportion of patients experiencing at least one inappropriate therapy (retrospective part) or more than one inappropriate therapy (prospective part) [ Time Frame: 15 months ]
    Study of the relationship between the detection of ID, the corrective action taken and the recurrence of ID of the same mechanism.

Secondary Outcome Measures :
  1. Number of diagnoses per patient per year and relative proportion of patients with at least one diagnosis [ Time Frame: 15 months ]

    The number of diagnoses per patient per year and the associated proportion of patients (with at least one diagnosis) will be measured. This will give the incidence rate of experiencing special classes of diagnoses over the 15-months follow-up period. The following subclasses will be assessed:

    Appropriate or not diagnoses, ID without therapy, therapies defined as shocks or antitachycardia pacing (ATP), shocks, inappropriate shocks, recurrence of ID and recurrence of inappropriate shocks.

    The prospective part will be compared to the retrospective part.

  2. Relative proportion of patients with a second day of ID [ Time Frame: 15 months ]

    Knowing that the intervals between ID days cannot be predetermined (non normal distribution), medical reaction time anticipated with Home Monitoring® can reduce the number of patients with a second day of ID.

    The proportion of patients with more than one inappropriate diagnosis will be measured.

  3. Number of Asymptomatic Inappropriate therapy and Inappropriate therapy without diagnosis [ Time Frame: 15 months ]
    Knowing that the main added value of Home Monitoring® relates on asymptomatic inappropriate therapies and inappropriate diagnoses without therapy (IDWT), the number of asymptomatic IT or IDWT patient per year and the associated proportion of patients (with at least one inappropriate diagnosis) will be measured.

  4. Time to the first ID [ Time Frame: 15 months ]
    The time from the enrolment until the first EGM revealing the ID will be assessed.

  5. Medical reaction time to the ID [ Time Frame: 15 months ]

    The time from the first ID to the follow-up visit during which a corrective action is taken is defined as the medical reaction time and will be assessed.

    In case of hospitalization without a follow-up visit (lead replacement for instance), the first day of hospitalization will be considered as the follow-up visit date.

    In current practice, the patients receiving shocks are advised to call their physicians in order to have their ICD interrogated. The analysis will distinguish the symptomatic IT and the asymptomatic ID (asymptomatic IT or IDWT).

  6. Number of days of recurrence within the medical reaction time [ Time Frame: 15 months ]
    The number of days with at least one ID within the medical reaction time is defined as the number of days of recurrence and will be evaluated with the associated proportion of patients. The analysis will distinguish the symptomatic IT and the asymptomatic ID (asymptomatic IT or IDWT).

  7. Effectiveness of the corrective action and analysis according to the initial ID type [ Time Frame: 15 months ]

    The proportion of patients with at least one inappropriate diagnosis recurrence (first day of recurrence) after the corrective action, and with the same ID mechanism as the original one, will be evaluated.

    A subgroup analysis depending on the ID mechanism will be performed, considering the inhomogeneous efficiency of the corrective action depending on the initial mechanism of the inappropriate diagnosis/therapy .

    The time from the follow-up visit during which the corrective action is taken until the next ID will be measured to assess the effectiveness of the corrective action.

  8. Classification of ID [ Time Frame: 15 months ]

    The proportion of patient in the following classes of ID episodes will be evaluated:

    • Atrial fibrillation,
    • Other forms of supraventricular tachyarrhythmia
    • Sinus tachycardia
    • Abnormal sensing (T wave oversensing, interferences,…)
    • Other: the comparison is performed as an inter observer comparison between the Adjudication Board's and the physician's classification.

  9. Total number of hospitalizations/deaths related to ID and IT [ Time Frame: 15 months ]
    Knowing that inappropriate therapies are among the heaviest ICD side-effects, the total number of hospitalizations and deaths related to ID or IT will be assessed.

  10. Risk of all-cause mortality [ Time Frame: 15 months ]
    The risk of death associated with inappropriate therapy only, with the inappropriate shocks only, with any shocks, without any therapy, without any shocks will be evaluated.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Population implanted of ICD with Biotronik Home Monitoring® system. 512 patients will be selected by investigators in 50 centers in France.

Inclusion Criteria:

  • Subject implanted with a single, dual, or triple chambers ICD within the last 3 months
  • Home Monitoring® activated and functional since hospital discharge
  • Patient willing and able to comply with the protocol and who has provided written informed consent about Home Monitoring®,
  • Patient whose medical situation is stable

Exclusion Criteria:

  • ICD replacements
  • New York Heart Association Function Class IV patients
  • Pregnant women or women who plan to become pregnant during the trial
  • Presence of any disease, other than patient's cardiac disease, associated with reduced likelihood of survival for the duration of the trial, e.g. cancer, uraemia (urea > 70mg/dl or creatinine >3mg/dl), liver failure, etc.
  • Age < 18 years
  • Patient unable to handle the Biotronik's transmitter correctly
  • Change of residence expected during the study
  • Insufficient global system for mobile communication (GSM) coverage at patient's home
  • Participation in another clinical study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01594112

Show Show 55 study locations
Sponsors and Collaborators
Biotronik SE & Co. KG
Layout table for investigator information
Principal Investigator: Jean-Claude DEHARO, Pr. Dr. Hôpital La Timone, 264 rue St. Pierre, 13385 MARSEILLE Cedex 5
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Biotronik SE & Co. KG Identifier: NCT01594112    
Other Study ID Numbers: HS056
First Posted: May 8, 2012    Key Record Dates
Last Update Posted: March 17, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Biotronik SE & Co. KG:
Remote monitoring
Home monitoring
Defibrillators, Implantable cardioverter-defibrillator
Inappropriate diagnoses and Therapies
Corrective actions
ID recurrences
Medical reaction time
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Tachycardia, Ventricular
Death, Sudden, Cardiac
Ventricular Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Cardiac Conduction System Disease
Heart Arrest
Death, Sudden